

REVIEW ARTICLE
OPEN

Multilayered regulation of cytoskeletal protein abundance: autoregulatory mechanisms of actin and tubulin

 Yena Cho^{1,2} and Yong Kee Kim  

© The Author(s) 2025

Structural proteins such as actin and tubulin form the fundamental framework of the cytoskeleton and are essential for diverse cellular processes, including morphogenesis, intracellular transport and cell division. Maintaining precise intracellular levels is crucial for cellular homeostasis because both excess and deficiency can lead to cytotoxicity. Although transcriptional regulation establishes basal expression levels, recent studies have highlighted the crucial role of post-transcriptional and post-translational mechanisms in the fine-tuning of cytoskeletal protein abundance in response to dynamic cellular demands. Actin and tubulin use distinct autoregulatory strategies. Tubulin mRNA undergoes cotranslational decay, mediated by TTC5 and tightly regulated by the CARM1–PI3KC2α axis, linking ribosome-associated quality control with post-translational modifications. Conversely, actin regulation involves mRNA localization via ZBP1 and spatially restricted translation, coupled with a G-actin–MRTF/SRF transcriptional feedback loop. In addition, the ubiquitin–proteasome system modulates cytoskeletal protein turnover and fine-tunes microtubule dynamics. The dysregulation of these pathways has been implicated in various human diseases, including tubulinopathies, cancer and myopathies. In this Review, we summarize the multilayered regulatory networks that control actin and tubulin abundance, highlight recent advances in autoregulatory circuits and their disease relevance, and discuss future research directions for the therapeutic targeting of cytoskeletal proteostasis.

Experimental & Molecular Medicine (2026) 58:59–72; <https://doi.org/10.1038/s12276-025-01615-w>

INTRODUCTION

Mammalian cells are supported by three major types of cytoskeletal structures: actin filaments; microtubules composed of α - and β -tubulin heterodimers; and intermediate filaments, such as keratin, vimentin and desmin¹. These cytoskeletal components provide structural integrity, maintain the cell shape and facilitate intracellular transport and motility^{2,3}. Actin and tubulin are the most abundantly expressed proteins in eukaryotic cells³. These high levels of expression present a substantial regulatory challenge: insufficient levels impair fundamental cellular functions, while excessive accumulation disrupts cytoskeletal dynamics, impairs organelle function, promotes protein aggregation and activates stress response pathways, ultimately leading to cellular toxicity^{4–6}. To maintain cytoskeletal homeostasis, cells use multilayered regulatory systems capable of precisely and flexibly controlling the expression and activity of actin and tubulin^{3,5,7}.

Transcriptional regulation provides a foundational framework for establishing the basal expression levels of cytoskeletal proteins in a cell type- and developmental stage-specific manner^{8–10}. However, cellular demand for these proteins is often dynamic and fluctuates rapidly in response to environmental and physiological cues. As such, transcriptional control alone is insufficient to meet the immediate and context-specific requirements for cytoskeletal remodeling. Several studies have highlighted the essential roles of post-transcriptional and post-translational mechanisms in fine-tuning the abundance of cytoskeletal proteins with temporal

precision^{11–15}. A well-characterized example of such regulation is autoregulation, which is a feedback loop that is responsive to the levels of unpolymerized cytoskeletal monomers^{16,17}. Elevated levels of monomeric G-actin inhibit further synthesis of the actin protein, thereby preventing excess accumulation^{16,18,19}. Autoregulation of tubulin is mediated by a cotranslational feedback mechanism that directly senses free tubulin levels. When excess free tubulin binds to nascent tubulin chains emerging from the ribosome, it induces ribosome stalling and promotes selective degradation of the translated mRNA^{17,20–22}. In addition to regulating mRNA levels, cytoskeletal protein abundance is modulated by the ubiquitin–proteasome system (UPS)²³. For instance, γ -actin is targeted for degradation by the E3 ubiquitin ligase, tripartite motif-containing protein 3 (TRIM3)²⁴, while α - and β -tubulin are regulated by the E3 ligase Parkin²⁵. Together, these post-transcriptional and post-translational mechanisms constitute a highly responsive and integrated regulatory system that adjusts cytoskeletal protein levels in accordance with basal requirements and dynamic functional demands. These regulatory layers act as active guardians of cellular structure and homeostasis, rather than serving as passive outputs of gene expression.

In this Review, we provide an integrated overview of the molecular mechanisms that regulate the expression and turnover of highly expressed cytoskeletal proteins, with particular focus on actin and tubulin. Beginning with transcriptional regulation, we explored the subsequent layers of control, including mRNA

¹Muscle Physiome Research Center and Research Institute of Pharmaceutical Sciences, Sookmyung Women's University, Seoul, Republic of Korea. ²College of Pharmacy, Sookmyung Women's University, Seoul, Republic of Korea. [✉]email: yksnbk@sookmyung.ac.kr

Received: 3 August 2025 Revised: 6 October 2025 Accepted: 20 October 2025
 Published online: 8 January 2026




Fig. 1 Phylogenetic analysis of actin isoforms and tubulin isotypes in humans, mice and rats. **a** Guide tree of actin isoforms from humans, mice and rats. The analysis includes six actin isoforms from each species: *ACTA1*, *ACTA2*, *ACTB*, *ACTC1*, *ACTG1* and *ACTG2*. Isoforms from humans, mice and rats are color-coded in blue, purple and pink, respectively. **b** Guide tree of tubulin isotypes from humans, mice and rats. The analysis includes nine α -tubulin (*TUBA*) and nine β -tubulin (*TUBB*) isotypes, as well as γ -tubulin (*TUBG*) from each species. Isoforms from humans, mice and rats are shown in blue, purple and pink, respectively. Guide trees were generated using neighbor-joining methods, and tree scales are indicated at the bottom of each panel.

stability, translational regulation and proteasomal degradation. We conclude by discussing the emerging feedback circuits and their physiological and pathological implications.

TRANSCRIPTIONAL REGULATION OF CYTOSKELETAL PROTEIN GENES

Transcriptional regulation provides an essential framework for controlling cytoskeletal protein abundance, enabling cells to adjust actin and tubulin gene expression in response to developmental, differentiation and environmental factors. Although transcriptional control is not solely responsible for maintaining precise protein levels, it also underpins higher-order regulatory mechanisms.

GENE FAMILY ORGANIZATION

In higher eukaryotes, actin and tubulin are encoded by evolutionarily conserved multigene families (Fig. 1). The human genome contains six actin isoforms with distinct and sometimes overlapping tissue-specific expression patterns²⁶. Some are muscle specific, whereas others, such as *ACTB* and *ACTG1*, are ubiquitously expressed^{27–29}. Knockout studies in mice have demonstrated that individual isoforms have specialized and nonredundant functions^{27,28}. Actin promoters contain conserved *cis*-regulatory motifs (TATA box, CArG box and CCAAT box) that enable both basal- and tissue-specific transcription via general and specialized transcription factors^{30–33}. For instance, β -actin expression is broadly maintained but can be modulated by serum response factor (SRF) and NF- γ ^{34,35}, while muscle-specific isoforms are regulated by muscle-specific regulatory factors such as MEF-2³⁶. Post-transcriptional mechanisms, including mRNA stability and translation efficiency, further refine isoform abundance^{27,28}. Similarly, nine isotypes each of α - and β -tubulin exist in humans, with unique tissue expression profiles^{10,37}. Tubulin genes are mainly transcribed by general transcription factors to sustain cytoskeletal homeostasis; however, certain isotypes are also regulated by specific transcription

factors and epigenetic modifications depending on the cellular context. For example, *TUBB3* is controlled by factors, such as AP-1, SP1, HREs and AREs and its expression is modulated by DNA methylation and histone modifications, particularly in cancer^{38–40}. These layers of regulation ensure cell type- and context-specific expression of cytoskeletal proteins^{41–44}.

TISSUE-SPECIFIC AND SIGNAL-DEPENDENT EXPRESSION

Cytoskeletal gene expression is dynamically regulated during development and exhibits a clear tissue specificity⁴⁵. Among the actin isoforms, *ACTA1*, *ACTA2*, *ACTC1* and *ACTG2* are muscle specific, whereas *ACTB* and *ACTG1* are ubiquitous²⁶ (Fig. 2a). During early cardiac development, skeletal and cardiac α -actin are both expressed, with skeletal α -actin initially being more abundant. As the heart matures, cardiac α -actin expression increases and becomes the predominant isoform in the adult myocardium⁴⁶. This isoform switch is essential for cardiac morphogenesis and function. Consistent with this, knockout studies in mice have highlighted the essential roles of specific isoforms during development, with *Actg1* deletion causing developmental abnormalities⁴⁷ and *Actb* loss resulting in embryonic lethality⁴⁸. Tubulin isotypes showed similar diversity; some were broadly expressed, whereas others displayed strong cell type specificity (Fig. 2b). For example, *TUBA1A* is strongly enriched in developing and post-mitotic neurons, whereas other α -tubulin isotypes (for example, *TUBA1B* and *TUBA1C*) exhibit broader, more ubiquitous expression. By contrast, *TUBB3* is widely expressed in neurons throughout both the central and peripheral nervous systems^{49–51}. Mutations in *TUBA1A* are associated with severe brain malformations^{52,53}, highlighting the importance of isotype-specific expression during neurodevelopment. The functional diversity of tubulin isotypes is underpinned by their structural features: while the N-terminal region is highly conserved, typically containing MREI or MREC motifs (Fig. 2b), the C-terminal region is markedly diverse. The latter not only serves as a hotspot for post-translational modifications (PTMs) but also provides a critical interface for

		Gene	Isoforms	N-terminal	Tissue expression			
actin	ACTA1	α skeletal	MCDEDETTALVCDNGSGLVKAGFAG	Skeletal muscle; Skeletal muscle contraction				
	ACTC1	α cardiac	MCDEDETTALVCDNGSGLVKAGFAG	Cardiac muscle (heart); Cardiac contraction				
	ACTA2	α smooth muscle	MCEEEDSTALVCDNGSGLCKAGFAG	Vascular & visceral smooth muscle; Smooth muscle contraction				
	ACTG2	γ smooth muscle	MC-EETTALVCDNGSGLCKAGFAG	Visceral smooth muscle (GI, bladder, uterus); Smooth muscle contraction (viscera)				
	ACTB	β cytoplasmic	M---DDIAALVVDNGSGMKAGFAG	Ubiquitous (all tissues); General cytoskeletal functions				
	ACTG1	γ cytoplasmic	M---EEEIAALVIDNGSGMKAGFAG	Ubiquitous (non-muscle cells); Cytoskeleton, migration				
		Gene	Isotypes	N-terminal	Tissue expression			
α-tubulin	TUBA1A	α1A	MRECISIHVG	Highly expressed in neurons (essential for brain development); ubiquitous in embryogenesis				
	TUBA1B	α1B	MRECISIHVG	Ubiquitous, broad expression; enriched in many tissues				
	TUBA1C	α1C	MRECISIHVG	Ubiquitous, broadly expressed in most tissues				
	TUBA3C	α3C	MRECISIHVG	Low expression; testis-enriched; also in some embryonic tissues				
	TUBA3D	α3D	MRECISIHVG	Testis-specific or enriched; low elsewhere				
	TUBA3E	α3E	MRECISIHVG	Mainly testis; little known about function elsewhere				
	TUBA4A	α4A	MRECISIHVG	Broad expression; enriched in neurons and muscle tissues; associated with ALS				
	TUBA4B	α4B	MRHQTERQD	Oocyte, respiratory, oviduct				
	TUBA8	α8	MRECISIHVG	Eye, testis, and muscle; low in most other tissues; related to ocular and brain development disorders				
		Gene	Isotypes	N-terminal	Tissue expression			
β-tubulin	TUBB	β	MREIVHIQAG	Ubiquitous, expressed in most tissues (considered "housekeeping")				
	TUBB1	β1	MREIVHIQIG	Highly specific to megakaryocytes and platelets; involved in platelet formation				
	TUBB2A	β2A	MREIVHIQAG	Broad expression; enriched in brain and testis				
	TUBB2B	β2B	MREIVHIQAG	Primarily in the brain; critical for neuronal migration and development				
	TUBB3	β3	MREIVHIQAG	Neuron-specific; enriched in the central and peripheral nervous system; widely used as a neuronal marker				
	TUBB4A	β4A	MREIVHIQAG	High in brain (especially oligodendrocytes); involved in myelination; mutations cause leukodystrophy				
	TUBB4B	β4B	MREIVHIQAG	Broad expression; ubiquitous but moderate levels across tissues				
	TUBB6	β6	MREIVHIQAG	Broad expression; high in immune cells (macrophages, lymphocytes); related to immune functions and cytoskeletal remodeling				
	TUBB8	β8	MREIVLTQIG	Oocyte-specific; expressed in female reproductive tissues; essential for meiosis and female fertility				
		Gene	Isotypes	N-terminal	Gene	Isotypes	N-terminal	amino acid residues - color code
α-tubulin	TUBA1A	α1A	439 SVEGEGEEEGEEY 451	TUBB	β	430 AEEEDFGEAEAAA----- 444	gray other	
	TUBA1B	α1B	439 SVEGEGEEEGEEY 451	TUBB1	β1	430 AVL EEEDEEVTEAEMEPEDKGH 451	violet aromatic	
	TUBA1C	α1C	439 SADGE--DEGEYY 449	TUBB2A	β2A	430 ADEQGEFEEEEEDEA----- 445	red acidic	
	TUBA3C	α3C	439 SVEAEAEEG-EEY 450	TUBB2B	β2B	430 ADEQGEFEEEEEDEA----- 445	green basic	
	TUBA3D	α3D	439 SVEAEAEEG-EEY 450	TUBB3	β3	430 AEEEGEMYDEDEESEAOQPK- 450	post-translational modifications	
	TUBA3E	α3E	439 SVEAEAEEG-EAY 450	TUBB4A	β4A	430 AE-EGEFEEEEEAEVA----- 444	E polyglutamylation - major sites	
	TUBA4A	α4A	439 SYEDEDEGEE-- 448	TUBB4B	β4B	430 AEEEGFEEEEEAEVA----- 445	E potential modification sites	
	TUBA4B	α4B	-----	TUBB6	β6	430 ANDGEAEFEDDEEEIDG----- 446	▼ detyrosination possible	
	TUBA8	α8	439 SFEENE--GEEF 449	TUBB8	β8	430 AEEEEEDEEYAEEEVA----- 444	▼ Δ2-/Δ3-tubulin possible	

Fig. 2 Actin isoforms and tubulin isotypes in humans. a,b A summary of the six human actin isoforms (a) and nine α-tubulin and nine β-tubulin isotypes (b). In a, the N-terminal sequences of actin isoforms are displayed, with sequence differences highlighted in pink. The gray regions at the N terminus indicate segments that are proteolytically removed and subsequently acetylated. In the case of β-actin, the processed N-terminus can also be arginylated. In b the N-terminal sequences of α-tubulin and β-tubulin isotypes are highly conserved, except for tubulin α4B, which shows some divergence. Sequence variations are highlighted in pink. Notably, the MREC motif (green) in α-tubulin and the MREI motif (blue) in β-tubulin are highly conserved across isotypes; these motifs are essential for autoregulation as they mediate interaction with TTC5 (Fig. 3). c Diversity of C-terminal tails and PTMs in human tubulin isotypes. Amino acids are color-coded according to their biochemical properties. Experimentally validated polyglutamylation sites are highlighted in bold, while all glutamate residues are shown as potential modification sites. Documented C-terminal truncations of α-tubulins are marked with '▼'.

interactions with microtubule-associated proteins (MAPs) and motor proteins (Fig. 2c). Although the mechanisms dictating isotype choice remain unclear, transcriptional regulation remains central. Meanwhile, cytoskeletal gene expression is rapidly modulated by external signals such as serum, growth factors (for example, EGF and PDGF) and mechanical stimuli, which drive changes in cell morphology, adhesion and motility^{54–56}. A classic example is the activation of actin genes by SRF, which binds to CArG boxes in actin promoters. SRF activity is regulated by Rho-family GTPases and cooperates with myocardin-related transcription factors (MRTFs), whose nuclear localization is controlled by G-actin levels, thereby linking actin dynamics directly to transcription^{57–59}. Tubulin gene regulation is more context dependent and involves diverse *cis*-regulatory elements in promoters, introns and untranslated regions (UTRs). For instance, elements, such as β2UE1 (spermatogenesis) and homeodomain/E-box motifs (neuronal α1-tubulin), mediate tissue- and stage-specific expression^{60–63}. Additional regulations involve p53-binding intron regions (repression)⁶⁴ and HIF-1α-binding 3'-flanking regions (induction under hypoxia)⁶⁵. However, the complete regulatory landscape of tubulin gene expression remains unclear.

AUTOREGULATORY MECHANISMS OF CYTOSKELETAL PROTEINS

Transcriptional regulation plays a pivotal role in establishing the basal expression levels of cytoskeletal proteins. However, they are often insufficient to accommodate rapid and context-specific fluctuations in protein demand. To achieve precise control of cytoskeletal protein abundance, mammalian cells use post-transcriptional regulatory strategies that modulate mRNA stability, degradation and subcellular localization. Among these, autoregulation is one of the most well-characterized mechanisms. This exemplifies the sophisticated feedback systems that operate at the mRNA levels to maintain cytoskeletal proteostasis. This mechanism underscores the extent to which cells have evolved multilayered and finely tuned regulatory networks to ensure dynamic and homeostatic control of highly abundant structural proteins.

COTRANSLATIONAL TUBULIN mRNA DECAY

The autoregulatory feedback mechanism that governs tubulin mRNA stability was first described in the 1980s²⁰. A key observation was that, under conditions of excess free tubulin, unspliced pre-mRNAs remained stable, whereas mature tubulin

mRNAs underwent selective degradation. This finding suggests that mRNA decay is tightly coupled with translation; that is, degradation is triggered specifically when ribosomes engage with mature transcripts^{17,20–22}. However, the molecular sensors and effectors mediating this feedback loop have remained unidentified for decades. A major conceptual breakthrough occurred in 2020 when the Hegde group uncovered a tetratricopeptide repeat domain 5 (TTC5)-dependent regulatory pathway that directly links nascent tubulin synthesis to cotranslational mRNA decay⁶⁶. TTC5 recognizes the conserved N-terminal motif of nascent α - and β -tubulin chains as they emerge from the ribosome. Upon binding, TTC5 recruits the adaptor protein SCAPER (S-Phase Cyclin A Associated Protein in the Endoplasmic Reticulum), the deadenylase complex CCR4–NOT (Carbon Catabolite Repression—Negative On TATA-less) and the substrate-recognition module CNOT11 (CCR4–NOT transcription complex subunit 11). This multicomponent complex facilitates selective degradation of the associated tubulin mRNA, thereby suppressing further tubulin synthesis^{66,67}.

Despite these advances, the upstream regulatory mechanisms that control TTC5 activation remain poorly understood. Recent work by the Kim group has proposed a novel coactivator associated arginine methyltransferase 1 (CARM1)-phosphatidylinositol 3-kinase type 2a (PI3KC2a)-TTC5 signaling axis that offers insight into this regulatory hierarchy⁶⁸ (Fig. 3). In its unmethylated form, PI3KC2a, a class II phosphatidylinositol 3-kinase previously implicated in endosomal trafficking and membrane remodeling⁶⁹, binds to TTC5 and inhibits its interaction with ribosome–nascent chain complexes. In this context, PI3KC2a functions as a negative regulator of tubulin autoregulation by sequestering TTC5 under steady-state conditions. Specifically, two mechanistically distinct modes of PI3KC2a regulation contribute to the control of tubulin autoregulation: one governs TTC5 activity and the other alters microtubule dynamics through arginine methylation. First, when CARM1-mediated methylation of PI3KC2a is reduced, it becomes less stable, leading to the release of TTC5. This, in turn, enables TTC5 to associate with ribosome–nascent chain complexes and initiate cotranslational mRNA decay⁶⁸. This mechanism underscores the role of PI3KC2a as a gatekeeper of TTC5 activity and highlights the importance of proteostasis in the dynamic regulation of cytoskeletal protein synthesis. Second, methylation of PI3KC2a at arginine 175 by CARM1 promotes microtubule polymerization and stability, thereby decreasing the intracellular pool of unpolymerized tubulin and indirectly suppressing activation of the autoregulatory machinery⁷⁰. Notably, this represents a previously unrecognized form of post-transcriptional control in which protein arginine methylation regulates mRNA stability via the modulation of an upstream regulatory scaffold.

However, this model also raises a fundamental mechanistic question: If methylated PI3KC2a no longer binds to TTC5, why does TTC5 not activate the autoregulatory response? Although methylation appears to reduce the affinity between PI3KC2a and TTC5, it is unclear whether this dissociation alone is sufficient for TTC5 activation. This ambiguity indicated the presence of additional regulatory layers. Notably, a recent study observed that newly synthesized $\alpha\beta$ -tubulin heterodimers sequester TTC5 and prevent its activation, whereas $\alpha\beta$ -dimers released from depolymerized microtubules lack this capacity⁷¹. This distinction implies that the biochemical origin of free tubulin, and not just its abundance, may influence TTC5 function. Moreover, differential PTMs on nascent versus recycled tubulin may serve as molecular signatures that guide TTC5 binding or activity. Clarifying these nuances is critical for achieving a more comprehensive understanding of how microtubule homeostasis is maintained through tightly coordinated layers of transcriptional and post-transcriptional regulation.

TRANSCRIPTIONAL REGULATION OF ACTIN AND ITS LOCALIZED TRANSLATION

The concept of the autoregulation of actin expression was first proposed in the 1990s⁷². Experimental studies have shown that total cellular actin protein levels remain remarkably stable, even when actin mRNA levels fluctuate considerably^{73,74}. This discrepancy suggests the presence of a compensatory feedback mechanism that maintains actin proteostasis at the post-transcriptional level⁷⁵. A key finding supporting this hypothesis is that the intracellular concentration of monomeric G-actin regulates the stability of actin mRNA. When the cytoskeleton is pharmacologically disrupted to increase G-actin levels, actin mRNA levels decrease, indicating that the polymerization state of actin directly influences gene expression^{18,19,76}. This establishes the existence of a feedback mechanism that links actin dynamics to mRNA stability. The molecular basis for this feedback was elucidated in the early 2000s, when researchers identified a specific nucleotide sequence—referred to as the zipcode—within the 3'-UTR of *ACTB* mRNA^{77,78}. This zipcode is recognized by the RNA-binding protein zipcode-binding protein 1 (ZBP1; also known as IGF2BP1), which binds to mRNA and directs it along the microtubules toward the leading edge of migrating cells^{79–81}. At this subcellular location, *ACTB* mRNA undergoes localized translation, thereby enabling spatial control of actin synthesis⁸¹. This mechanism demonstrates that mRNA localization and translational regulation are closely coupled and play crucial roles in coordinating cytoskeletal dynamics with cell polarity and motility (Fig. 4).

In addition to post-transcriptional control, actin expression is regulated at the transcriptional level through a feedback circuit involving the MRTF–SRF transcriptional complex⁵⁷. G-actin binds to the RPEL motifs in MRTF-A, sequestering it in the cytoplasm and preventing its entry into the nucleus^{57,82,83}. Because actin genes are direct transcriptional targets of SRF⁸⁴, this interaction creates a classical negative feedback loop⁸⁵. Specifically, an increase in G-actin leads to a greater sequestration of MRTF, which reduces SRF-mediated transcriptional activity, thereby decreasing the transcription of actin genes and ultimately reducing actin protein synthesis^{34,86}. Interestingly, actin is not confined to the cytoplasm, but also exists in the nucleus, where it plays important regulatory roles^{87–92}. Nuclear G-actin is actively maintained by importin-9 and cofilin. Unphosphorylated cofilin binds G-actin and forms a ternary complex with importin-9, facilitating cytoplasm-to-nucleus transport and supporting transcription and chromatin regulation, whereas its phosphorylation inhibits this import^{93,94}. Actin export from the nucleus is mediated by exportin-6, which recognizes the profilin–actin heterodimer in a Ran-GTP-dependent manner⁹⁵. Profilin promotes ADP–ATP exchange, enabling ATP-actin to be efficiently reused in cytoplasmic filament elongation⁹⁶. This nucleocytoplasmic shuttling is dynamically regulated by the intracellular G-actin/F-actin ratio. Within the nucleus, G-actin reinforces the inhibition of transcriptional feedback by binding to MRTFs and attenuating their transcriptional activity⁵⁸. In response to specific stimuli, such as signaling cues, stress or differentiation, nuclear G-actin polymerizes into F-actin⁹⁷, relieving MRTF inhibition and triggering SRF-dependent transcription. This dynamic shift not only promotes actin gene expression but also exemplifies how the cytoskeletal state directly influences nuclear transcriptional programs.

This multilayered regulatory system allows the cells to finely tune the expression of actin or tubulin in response to the cytoskeletal status and mechanical demands of the environment. The key features of actin and tubulin autoregulation are summarized in Table 1. This feedback system ensures that actin is synthesized only when needed and prevents overaccumulation, which can disrupt cellular functions. Although notable mechanistic insights into actin autoregulation were obtained in the early




Fig. 3 Mechanistic model of tubulin autoregulation via the CARM1-PI3KC2 α -TTC5 signaling axis. PI3KC2 α acts as a key regulatory factor in the tubulin autoregulatory pathway by binding to and sequestering TTC5, thereby suppressing TTC5-mediated cotranslational decay of tubulin mRNA. The release of TTC5 can be triggered via two distinct mechanisms: first, proteasomal degradation of PI3KC2 α reduces its cellular abundance, resulting in the liberation of TTC5 (right); second, CARM1-mediated methylation of PI3KC2 α diminishes its binding affinity for TTC5, thereby facilitating TTC5 release (left). Unmethylated PI3KC2 α is inherently unstable and undergoes rapid degradation through the UPS, leading to a decrease in PI3KC2 α levels and an accumulation of unpolymerized tubulin in the cytosol. Under these conditions, freed TTC5 associates with the MREC or MREI motif located at the N terminus of nascent tubulin chains emerging from ribosomes, thereby initiating cotranslational mRNA decay and activating the tubulin autoregulatory circuit. Conversely, when PI3KC2 α is methylated by CARM1, it promotes microtubule polymerization and stabilizes microtubule networks, which in turn reduces the cytosolic pool of unpolymerized tubulin. In this methylated state, even if TTC5 is released, the limited availability of free tubulin or newly translated tubulin dimers fails to effectively trigger TTC5-mediated mRNA decay, thereby maintaining suppression of the autoregulatory pathway.

2000s, advances in this field have been relatively limited over the past two decades. By contrast, tubulin autoregulation has emerged as a highly dynamic and complex regulatory network that integrates multiple layers of control, including cotranslational

mRNA surveillance, proteasome-mediated degradation and signaling pathways responsive to cellular stress and mitotic demand^{56–68,70,71}. This disparity in regulatory complexity probably reflects intrinsic biological differences between actin and tubulin.




Fig. 4 Autoregulatory mechanisms controlling intracellular actin level. This schematic illustrates the major autoregulatory mechanisms that control intracellular actin levels. At the transcriptional level, excess cytoplasmic G-actin binds to MRTF, sequestering it in the cytoplasm and thereby preventing its nuclear translocation. This interaction inhibits SRF-dependent transcription of actin genes, establishing a negative feedback loop that suppresses *ACTB* mRNA synthesis under conditions of elevated G-actin. At the post-transcriptional level, *ACTB* mRNA is recognized by ZBP1 and transported along microtubules to specific subcellular regions, where localized translation occurs. The newly synthesized actin monomers are then polymerized into filamentous F-actin, which can depolymerize back into G-actin, forming a feedback circuit that links transcriptional and translational control. Nuclear actin dynamics are further regulated by the nucleocytoplasmic shuttling of G-actin mediated by importin-9 and cofilin for nuclear import, and exportin-6 and profilin for nuclear export. Within the nucleus, G-actin binds MRTFs and inhibits SRF-dependent actin gene transcription. In response to specific stimuli, nuclear G-actin can also polymerize into F-actin, which contributes to nuclear functions such as chromatin accessibility, transcription and DNA damage repair. These multilayered regulatory mechanisms enable precise spatiotemporal control of actin expression in response to cellular demands. NPC, nuclear pore complex.

Microtubules are central to highly dynamic processes, such as mitosis, vesicle trafficking and rapid structural remodeling, and thus require more rapid and precise control. Actin, although essential for many cellular processes, exhibits comparatively stable dynamics and is, therefore, subject to less complex autoregulatory control.

PROTEIN TURNOVER: THE UPS

The maintenance of cytoskeletal homeostasis requires not only the timely and appropriate synthesis of actin and tubulin but also the selective degradation of excess, misfolded or unassembled proteins. To achieve this, cells have evolved sophisticated protein quality control mechanisms, of which the UPS plays a central role in targeting cytoskeletal proteins and their regulatory factors for proteolytic degradation^{98,99}. In this pathway, target proteins are tagged with polyubiquitin chains by E3 ubiquitin ligases, which mark them for recognition and subsequent degradation by the

26S proteasome¹⁰⁰. Unlike several signaling proteins or metabolic enzymes, actin and tubulin assemble into large dynamic polymers, and dysregulation of their polymerization dynamics can lead to cytoskeletal instability, proteotoxic stress and pathological protein aggregation. Therefore, the precise control of actin and tubulin, as well as their regulatory proteins, is essential for maintaining cytoskeletal integrity. Degradation of cytoskeletal regulators via the UPS is a critical component of this control, allowing the cell to fine-tune cytoskeletal assembly and remodeling in response to physiological demands. This degradation system broadly contributes to key cellular functions including migration, division and intracellular transport. Table 2 summarizes the ubiquitination sites and functional roles of actin, tubulin and their respective regulatory proteins. In this section, we discuss how ubiquitin-mediated degradation regulates actin and tubulin abundance, with particular emphasis on the turnover of associated regulatory proteins and their implications for cytoskeletal proteostasis.

Table 1. The key features of actin and tubulin autoregulation.

Category	Actin	Tubulin
Definition	Regulation by free G-actin levels	Regulation by free $\alpha\beta$ -tubulin dimer levels
Regulation mode	High G-actin levels regulate actin gene transcription via the MRTF/SRF pathway	CARM1-PI3KC2 α -TTC5 axis controls tubulin mRNA stability
Mechanism	G-actin sequesters MRTFs, blocking SRF-dependent transcription	Nascent N-terminal motif recruits TTC5 to trigger cotranslational mRNA decay
Target Genes	β -Actin genes, other cytoplasmic actin genes	α - and β -tubulin genes (with MREC or MREI motif)
Physiological Role	Actin dynamics, motility, transcription, DNA repair, mechanotransduction	Microtubule dynamics, mitosis, transport
Features	Transcriptional feedback loop sensitive to G-actin levels; relatively slow due to transcriptional control	Rapid post-transcriptional regulation via mRNA decay, enabling swift adjustment of tubulin protein levels

UBIQUITINATION OF ACTIN AND ITS REGULATORS

So far, studies on the ubiquitination of actin itself remain limited; however, polyubiquitination of γ -actin by TRIM3 has been reported²⁴. Conversely, the ubiquitination of actin-regulatory proteins has been more extensively investigated, particularly those involved in actin cytoskeletal remodeling, such as Rho family GTPases (for example, Rac1, RhoA and Cdc42), their downstream effectors (for example, PAK1 and ROCK2) and actin-binding proteins, such as cofilin. Rac1, a key regulator of lamellipodia formation and cell motility, is ubiquitinated by multiple E3 ligases, including HACE1¹⁰¹, inhibitors of apoptosis (IAPs)¹⁰² and SCF^{FBXL19} (ref. ¹⁰³), thereby modulating its stability and activity in dynamic cellular processes, such as migration. RhoA, which governs stress fiber formation and cell polarity, is ubiquitinated by several E3 ligases, such as CUL3/BACURD¹⁰⁴, SCF^{FBXL19} (ref. ¹⁰⁵) and Smurf1¹⁰⁶, and has functional implications for cell motility, morphogenesis and cancer progression. Cdc42, another member of the Rho GTPase family involved in filopodia formation and polarity establishment, is targeted by XIAP for ubiquitination, and this process has been linked to the suppression of tumor metastasis¹⁰⁷. The downstream effectors of Rho GTPases also undergo ubiquitin-mediated regulation. PAK1, a serine/threonine kinase activated by Rac1 and Cdc42, can be degraded in response to the anti-parasitic drug ivermectin, although the responsible E3 ligase remains unidentified. This degradation has been associated with the inhibition of cancer cell proliferation¹⁰⁸. ROCK2, a RhoA effector involved in contractility and cytoskeletal tension, is ubiquitinated by the anaphase-promoting complex/cyclosome (APC/C), a process that is crucial for maintaining neuronal stability¹⁰⁹. Cofilin, a key actin-depolymerizing factor, is phosphorylated at Ser3 and Tyr68 before ubiquitination and subsequent degradation. This modification cascade effectively attenuates its depolymerization activity, contributing to actin filament stabilization under specific physiological conditions¹¹⁰. Collectively, while direct ubiquitination of actin is relatively rare, targeted degradation of actin regulatory proteins through the UPS represents a central mechanism for the fine-tuned control of actin cytoskeletal dynamics and associated cellular functions.

UBIQUITINATION OF TUBULIN AND ITS REGULATORS

Tubulin ubiquitination was first reported in 1988 when it was observed that the microtubule network could associate with ubiquitin¹¹¹. Initially, this phenomenon was primarily attributed to the presence of MAPs rather than tubulin itself¹¹¹. However, subsequent studies revealed that α , β - and γ -tubulin subunits can also undergo direct ubiquitination¹¹². For example, the E3 ubiquitin ligase Parkin mediates the ubiquitination of $\alpha\beta$ -tubulin heterodimers, promoting their degradation or recycling²⁵. In addition, E3 ligase complexes containing CUL1, CUL4A and CUL4B

have been shown to ubiquitinate γ -tubulin as well as γ -tubulin complex proteins (GCP2 and GCP3), which are essential for microtubule nucleation at the centrosome¹¹². Among the best-characterized ubiquitinated MAPs is Tau. Tau, a neuronal microtubule-stabilizing protein implicated in neurodegenerative diseases, is regulated by several E3 ligases^{113,114}. CHIP, in cooperation with HSP70, promotes Tau ubiquitination and degradation¹¹³, and the E4 ligase UBE4B extends polyubiquitin chains to enhance degradation efficiency¹¹⁵. In addition, Praja1 has been identified as a novel E3 ligase that ubiquitinates Tau, contributing to its proteasomal turnover¹¹⁴.

Although actin ubiquitination is largely associated with proteasomal degradation, tubulin ubiquitination can also have nonproteolytic regulatory functions. For example, the BRCA1 (breast cancer susceptibility protein 1)-BARD1 (BRCA1 associated RING domain 1) complex monoubiquitinates γ -tubulin, a modification implicated in the regulation of centrosome number^{116,117}. Similarly, mahogunin ring finger 1 (MGRN1) catalyzes the K6-linked polyubiquitination of α -tubulin, which does not trigger degradation but contributes to microtubule stabilization and spindle positioning^{118,119}. In summary, the UPS plays a crucial role in the maintenance of cytoskeletal homeostasis by regulating the abundance and turnover of tubulin and its associated proteins. This is achieved not only through degradation-oriented pathways but also via nondegradative ubiquitination that modulates microtubule dynamics. Continued investigation of these regulatory circuits is expected to advance our understanding of cytoskeletal remodeling under both physiological and pathological conditions.

IMPLICATIONS FOR DISEASE AND THERAPEUTIC OPPORTUNITIES

Tight regulation of actin and tubulin abundance is essential for preserving cellular structure and function. Disruption of this homeostatic balance contributes to the pathogenesis of numerous diseases with distinct consequences depending on the specific cytoskeletal system affected^{120,121}. Due to the divergent regulatory architectures governing actin and tubulin expression, including differences in feedback mechanisms, transcriptional control and post-transcriptional modulation, perturbations in homeostasis result in nonoverlapping disease phenotypes. Actin dysregulation has been predominantly implicated in skeletal and cardiac myopathies¹²², as well as angiogenesis-related pathologies¹²³. Given the complexity and ubiquity of actin networks, the direct pharmacological targeting of actin is often infeasible or nonspecific. Consequently, therapeutic strategies have largely focused on modulating upstream regulatory pathways, such as the Rho family of GTPases and the MRTF-SRF transcriptional axis¹²⁴, to restore actin-dependent functions in disease contexts^{125,126}. Conversely, aberrations in tubulin expression or

Table 2. Summary of the ubiquitination of cytoskeleton-associated proteins.

Substrate	E3 ubiquitin ligases	Ubiquitinated lysine residues	Function and characteristics	References
Regulation of actin expression and dynamics				
γ -Actin	TRIM3	*K18	Cotranslational polyubiquitination and degradation	²⁴
Cdc42	XIAP	K166	Proteasomal degradation	¹⁰⁷
Cofilin	Cbl	*K19, K92, K112, K144, K164	K48-linked ubiquitination and degradation	¹¹⁰
Formin mDia2	AIP4		K63-linked ubiquitination	¹⁹²
PAK1	–	*K118	Proteasomal degradation	¹⁰⁸
Profilin 1	–	–	Proteasomal degradation	¹⁹³
Rac1	HACE1	K70, K108	Proteasomal degradation	¹⁰¹
	cIAP1, XIAP	K147	Proteasomal degradation	¹⁰²
	SCFFbxL19	K147	Proteasomal degradation	¹⁰³
RhoA	CUL3/BACURD	K166	Proteasomal degradation; depends on AKT-mediated S71 phosphorylation	¹⁰⁴
	SCFFbxL19	–	Proteasomal degradation	¹⁰⁵
	Smurf1	K135	Proteasomal degradation; ERK2-mediated phosphorylation-dependent mechanism	¹⁰⁶
		K6, K7, K51	Proteasomal degradation; only the triple mutation (K6/7/51R) markedly reduces ubiquitination levels compared with WT or K6/7R; Smurf1 interacts with the dominant negative form of RhoA in vivo and with nucleotide-free or GDP-bound RhoA in vitro	¹⁰⁶
ROCK2	APC/C ^{Cdh1}	–	Proteasomal degradation	¹⁰⁹
Regulation of tubulin expression and dynamics				
α -Tubulin	MGRN1	*K60, K96, K112, K326	K6-linked polyubiquitination; promotes tubulin polymerization	^{118,119}
	Parkin		Proteasomal degradation	²⁵
β -Tubulin	Parkin	*K19, K58, K103, K252	Proteasomal degradation	²⁵
γ -Tubulin	BRCA1/BARD1	K48, K344	Monoubiquitination; regulates centrosome number	^{116,117}
	CUL1, CUL4A, CUL4B	*K48, K113	Proteasomal degradation; no impact of individual Lys-to-Arg mutations on protein levels	¹¹²
EB1	CRL3 ^{KHL21}	K100	Monoubiquitination; inhibits its interaction with microtubule, promoting microtubule disassembly	¹⁹⁴
	Unknown CRL related to CSN (proposed)	–	Proteasomal degradation	¹⁹⁵
EB3	SIAH-1	–	Proteasomal degradation	¹⁹⁶
GCP2	CUL1, CUL4A, CUL4B	*K50, K92, K347, K541, K735	Proteasomal degradation; because some ubiquitination sites are located within their γ -tubulin binding region, stability of GCP2 and GCP3 depends on binding to γ -tubulin	¹¹²
	CUL1, CUL4A, CUL4B		Proteasomal degradation	¹¹²
Tau	CHIP	*K257, K259, K267, K274, K281, K290, K321, K343, K353, K385	Proteasomal degradation; balance between CHIP and Hsp70 levels determine Tau levels; CHIP–Hsc70 complex ubiquitinates and degrades phosphorylated Tau in collaboration with Ubch5B	^{113,115}
	Praia1	–	Proteasomal degradation	¹¹⁴
	COP1	–	Proteasomal degradation	¹⁹⁷

*Putative ubiquitination sites from mass spectrometry data; not functionally validated.

dynamics are closely associated with neurodegenerative disorders¹²⁷, malignancies¹²⁸ and resistance to chemotherapeutic agents¹²⁹. Current therapeutic approaches frequently exploit the dynamic instability of tubulin using microtubule-targeting agents, such as taxanes and vinca alkaloids, which interfere with polymerization dynamics¹³⁰. However, these treatments are often limited by their toxicity and acquired resistance^{130,131}. A more nuanced understanding of tubulin regulation, particularly at the translational, autoregulatory and PTM levels, may enable the development of next-generation therapeutics that target specific regulatory nodes, minimize off-target effects and overcome resistance to treatment.

ACTIN DYSREGULATION AND DISEASE

Pathogenic mutations have been identified in all six human actin genes, each exhibiting distinct expression patterns and disease associations²⁷. Among these, *ACTA1*, which is exclusively expressed in the skeletal muscle, harbors the greatest number of disease-causing variants. Mutations in *ACTA1* are the predominant genetic cause of nemaline myopathy, a congenital disorder characterized by muscle weakness and respiratory impairment due to the formation of nemaline bodies in the muscle fibers^{132,133}. *ACTA2*, primarily expressed in smooth muscle, is the second most frequently mutated actin gene and is strongly linked to familial thoracic aortic aneurysm and dissection¹³⁴. Mutations in *ACTC1*, which is predominantly expressed in cardiac muscles, are associated with both hypertrophic and dilated cardiomyopathies^{135,136}, highlighting the essential role of actin in maintaining myocardial structure and function. Conversely, mutations in the ubiquitously expressed *ACTB* result in a broad spectrum of clinical manifestations, including developmental delays, cerebral malformations, defects in neuronal migration and progressive muscle atrophy, collectively referred to as Baraitser–Winter cerebrofrontofacial syndrome^{137,138}. Although *ACTG1* is widely expressed, pathogenic mutations in this gene tend to result in more restricted phenotypes^{139,140}. The least commonly mutated gene *ACTG2*, which is expressed specifically in smooth muscles, has been implicated in megacystis–microcolon–intestinal hypoperistalsis syndrome, a rare and severe congenital visceral myopathy^{141,142}. Despite the growing number of reported pathogenic actin variants, the molecular consequences of most mutations remain poorly understood. Ongoing *in vitro* and *in vivo* studies are aimed at delineating how these mutations alter actin polymerization dynamics, protein–protein interactions and cytoskeletal integrity to drive disease pathology.

In addition to these inherited disorders, dysregulation of actin dynamics plays a pivotal role in cancer metastasis¹⁴³, further underscoring the central importance of actin in human diseases. Unlike tubulin, whose total expression levels are often directly linked to metastasis¹⁴⁴, the role of actin in cancer progression primarily involves changes in actin dynamics rather than alterations in total protein levels¹⁴⁵. Key actin-binding proteins such as cofilin, the Arp2/3 complex, fascin, gelsolin and profilin regulate actin polymerization and turnover, driving processes such as lamellipodia and filopodia formation, which are essential for metastasis^{146–148}. In addition, actin mRNA localization to the leading edge and isoform switching between β -actin and γ -actin contribute to metastatic behavior^{149–151}. Thus, while the total actin abundance remains relatively stable, its spatial regulation and dynamic remodeling are central to the invasive and metastatic potential of cancer cells. Moreover, this dysregulation has been implicated in age-associated disorders and vascular pathologies, reflecting its critical roles in cell motility, adhesion, mechano-transduction and cell cycle progression¹⁵². Aberrant activation of the RhoA–ROCK signaling pathway contributes to endothelial dysfunction, vascular stiffening and thrombotic complications¹⁵³. A recent study demonstrated that constitutively active RhoA

mutants (G14V/Q63L) inhibit endothelial cell proliferation and migration¹⁵⁴, underscoring the pathological relevance of hyperactive RhoA signaling and the therapeutic potential of its inhibition.

Several pharmacological strategies have emerged to modulate actin dynamics, either by targeting upstream regulators or by directly interfering with actin filament assembly. ROCK inhibitors such as Fasudil, Ripasudil and Y-27632 have demonstrated therapeutic efficacy in preclinical and clinical models of vascular disease, neurodegeneration and glaucoma^{155,156}. In addition, small molecules that modulate the actin architecture through distinct mechanisms have been developed. These include Rho inhibitors (for example, C3 transferase¹⁵⁷ and Rhosin¹⁵⁸) and compounds that act directly on actin filaments. For instance, Cytochalasin D caps the barbed ends of F-actin, preventing polymerization¹⁵⁹; Latrunculin A sequesters G-actin monomers, thereby blocking filament assembly¹⁶⁰; and Jasplakinolide stabilizes and nucleates F-actin by binding to filamentous structures¹⁶¹. Although potent, these agents often elicit broad cytoskeletal disruption and exhibit cytotoxic effects, thereby limiting their clinical applicability. Thus, although pharmacological manipulation of actin dynamics holds considerable therapeutic promise, it remains technically challenging because of the ubiquitous and multifunctional nature of the actin cytoskeleton. Future advances in isoform-specific targeting, spatiotemporal delivery and context-dependent modulation of actin regulators may enable safe and precise correction of actin dysregulation in human diseases.

TUBULIN DYSREGULATION AND DISEASE

Mutations in specific tubulin isotypes underlie a spectrum of neurodevelopmental disorders collectively referred to as tubulopathies, which are characterized by malformations of cortical development, motor impairments, and epileptic seizures¹⁶². These conditions are most commonly associated with heterozygous missense mutations in *TUBA1A*^{52,163}, *TUBB2B*¹⁶⁴, *TUBB3*⁵¹, *TUBB4A*¹⁶⁵ and *TUBG1*^{166,167}. Among them, *TUBA1A* mutations, particularly at conserved residues such as R264, R402 and R422, are strongly associated with lissencephaly and central pachygryria. By contrast, mutations in *TUBB2B* (for example, A248, R380 and E421) and *TUBB3* (for example, E205 and E410) have been implicated in polymicrogyria-like cortical dysplasia and multifocal cortical malformations¹⁶⁸. These residues are located on the external surface of the tubulin dimer and participate in interdimer and intradimer interactions, suggesting that such mutations impair proper folding, dimerization and microtubule dynamics^{169,170}. Supporting this, recent studies have demonstrated that mutations in *TTC5* or *PIK3C2A*, which are key components of the tubulin autoregulatory pathway, also lead to neurodevelopmental abnormalities, including global developmental delay, ventricular enlargement and cerebral atrophy^{171,172}, highlighting the critical role of post-transcriptional regulation of tubulin homeostasis during brain development.

Intriguingly, despite the identification of over 290 pathogenic variants across tubulin genes, no disease-associated mutations have been reported at the K40 residue of α -tubulin or within the C-terminal tails of α - and β -tubulins¹⁷³. These regions are known hotspots of PTMs and mediate their interactions with MAPs¹⁷⁴. In particular, the α -tubulin K40 residue, located on the luminal face of microtubules, serves as a hotspot for diverse PTMs with distinct functional consequences. K40 acetylation by α -tubulin acetyltransferase 1 (α TAT1) stabilizes long-lived microtubules and enhances resistance to mechanical stress, intracellular transport and neuronal migration^{175,176}. By contrast, SETD2-dependent K40 trimethylation promotes mitotic fidelity and microtubule stability^{177,178}, whereas the recently described K40 lactylation exhibits differential enrichment on soluble versus polymerized tubulin, potentially modulating microtubule dynamics^{179,180}. These

modifications, which can compete for the same residue, collectively fine-tune microtubule behavior, cellular motility and neuronal development. Importantly, in the broader context of the tubulin code, such residue-specific PTMs act in combination with isotype diversity and C-terminal tail modifications to generate a regulatory language that dictates microtubule dynamics and MAP/motor binding. Their remarkable evolutionary conservation probably reflects their strong functional constraints. In support of this, deletion of the C-terminal tyrosine of α -tubulin in mice results in severe brain malformations and perinatal lethality¹⁸¹, and β -tubulin lacking its C-terminal tail can still polymerize but generates microtubules with aberrant dynamics and altered mechanical properties¹⁸². These findings highlight the essential contributions of PTMs to microtubule integrity, spatiotemporal dynamics and cellular resilience, thereby forming a mechanistic bridge between genetic lesions and structural cytoskeletal disruption.

Although genetic mutations highlight the role of tubulin in development, dysregulated expression and aberrant PTMs of tubulin are also critically involved in cancer progression and metastasis. Tumor cells frequently exhibit altered isotype compositions, PTM signatures and microtubule behavior^{183,184}. For instance, β -tubulin is overexpressed in lung, ovarian, breast and gastric cancers and is associated with increased tumor aggressiveness and poor response to therapy^{185–187}. Similarly, nuclear-localized β -tubulin correlates with adverse clinical outcomes in multiple cancer types¹⁸⁸. γ -Tubulin, classically associated with microtubule nucleation, is often upregulated and mislocalized to the nucleus in high-grade tumors such as glioblastoma multiforme¹⁸⁹. PTM dysregulation also drives chromosomal instability, enhanced motility and chemoresistance. For example, loss of tubulin tyrosine ligase like 1 (TTL11), a tubulin polyglutamylase, disrupts accurate chromosome segregation¹⁹⁰, and elevated α TAT1-mediated acetylation is observed in paclitaxel-resistant cells, reducing drug-induced apoptosis¹⁹¹.

These findings collectively highlight tubulin not only as a structural component, but also as a key regulator of both tumor progression and metastasis through isoform-specific expression, PTMs, autoregulation and dynamic remodeling of the microtubule network. Consequently, targeting tubulin-modifying enzymes or modulating PTMs offers promising therapeutic avenues, particularly in overcoming the limitations of conventional tubulin-targeting agents, such as taxanes (for example, paclitaxel) and vinca alkaloids (for example, vincristine), which often face resistance and dose-limiting toxicities^{130,131}.

CONCLUDING REMARKS AND FUTURE PERSPECTIVES

The precise regulation of cytoskeletal protein abundance is fundamental for maintaining cellular homeostasis, enabling cells to adapt dynamically to changing physiological demands. Among cytoskeletal proteins, actin and tubulin are particularly abundant and essential; however, they are regulated by distinct autoregulatory mechanisms that reflect their divergent biological roles and evolutionary pressures. Tubulin homeostasis is governed by a highly dynamic, multilayered autoregulatory system that integrates translational surveillance, proteostasis and signal-responsive feedback. The cotranslational mRNA decay pathway initiated by TTC5 upon sensing nascent tubulin chains ensures that excess free tubulin rapidly suppresses its own synthesis. This mechanism is further fine-tuned by upstream regulators, such as PI3KC2 α and its arginine methylation by CARM1, linking cytoskeletal dynamics to broader signaling pathways. The evolutionary elaboration of such a responsive and tightly coupled system probably reflects the critical role of microtubules in fast and reversible processes, such as mitosis, intracellular transport and rapid morphological remodeling. These functions require the real-time adaptation of tubulin abundance to the structural and

temporal demands of the cell, necessitating feedback systems with high temporal resolution and signal sensitivity. By contrast, actin autoregulation evolves through transcription-centric and spatially coordinated mechanisms. Although actin mRNA stability is influenced by the cellular G-actin pool, post-transcriptional feedback is limited in terms of scope and mechanistic complexity. Instead, actin expression is modulated through transcriptional feedback involving the MRTF–SRF pathway and the spatially restricted translation via zipcode-binding proteins. These systems appear to be sufficient to maintain actin levels in accordance with the relatively stable demand for cell shape maintenance, migration and adhesion. Unlike the rapid assembly–disassembly dynamics of microtubules, actin structures—particularly stress fibers and cortical actin—undergo slower remodeling, providing less immediate but more spatially regulated control.

Therefore, the evolutionary divergence of these autoregulatory strategies may reflect a tradeoff between spatial precision and temporal responsiveness, optimized for the distinct physiological roles of actin and tubulin. Tubulin regulation prioritizes speed and feedback sensitivity, while actin regulation emphasizes localization and structural integrity. However, several key questions remain to be addressed in future studies. For example, it remains unclear how various PTMs such as tubulin acetylation or actin phosphorylation modulate the activity and dynamics of their respective autoregulatory circuits. Another critical question is whether the distinct states between newly synthesized and depolymerized proteins act as molecular cues within these regulatory pathways. In the case of tubulin, maintaining an appropriate stoichiometric balance between α -tubulin and β -tubulin is essential, as these subunits form obligate heterodimers that constitute the fundamental building blocks of microtubules. Elucidating the molecular mechanisms and regulatory networks that control α / β -tubulin homeostasis represents a fundamental challenge and a key priority for future research. Furthermore, understanding how these autoregulatory pathways are dysregulated in pathological contexts, particularly in cancer and neurodevelopmental disorders, may reveal novel therapeutic targets and offer new opportunities for clinical interventions.

Future studies should aim to uncover additional layers of regulation, including the roles of RNA-binding proteins, alternative splicing, noncoding RNAs and organelle-specific degradation systems. Expanding our knowledge of cytoskeletal autoregulation will not only deepen our understanding of fundamental cell biology, but also inform strategies for modulating the cytoskeleton in clinical contexts where its balance is perturbed.

REFERENCES

1. Fletcher, D. A. & Mullins, R. D. Cell mechanics and the cytoskeleton. *Nature* **463**, 485–492 (2010).
2. Pollard, T. D. & Cooper, J. A. Actin, a central player in cell shape and movement. *Science* **326**, 1208–1212 (2009).
3. Huber, F., Boire, A., Lopez, M. P. & Koenderink, G. H. Cytoskeletal crosstalk: when three different personalities team up. *Curr. Opin. Cell Biol.* **32**, 39–47 (2015).
4. Lundin, V. F., Leroux, M. R. & Stirling, P. C. Quality control of cytoskeletal proteins and human disease. *Trends Biochem. Sci.* **35**, 288–297 (2010).
5. Gasic, I. & Mitchison, T. J. Autoregulation and repair in microtubule homeostasis. *Curr. Opin. Cell Biol.* **56**, 80–87 (2019).
6. Gasic, I., Boswell, S. A. & Mitchison, T. J. Tubulin mRNA stability is sensitive to change in microtubule dynamics caused by multiple physiological and toxic cues. *PLoS Biol.* **17**, e3000225 (2019).
7. Goodson, H. V. & Jonasson, E. M. Microtubules and microtubule-associated proteins. *Cold Spring Harb. Perspect. Biol.* **10**, a022608 (2018).
8. Poddar, R., Paul, S., Chaudhury, S. & Sarkar, P. K. Regulation of actin and tubulin gene expression by thyroid hormone during rat brain development. *Brain Res. Mol. Brain Res.* **35**, 111–118 (1996).
9. Fernandez-Barrera, J., Bernabe-Rubio, M., Casares-Arias, J., Rangel, L., Fernandez-Martin, L. et al. The actin–MRTF–SRF transcriptional circuit controls tubulin acetylation via alpha-TAT1 gene expression. *J. Cell Biol.* **217**, 929–944 (2018).

10. Gasic, I. Regulation of tubulin gene expression: from isotype identity to functional specialization. *Front. Cell. Dev. Biol.* **10**, 898076 (2022).
11. Goodier, M. R. & Kay, J. E. Post-transcriptional regulation of cytoskeletal actin and T lymphocyte receptor beta chain mRNA by phorbol ester. *Biochim. Biophys. Acta.* **1092**, 124–127 (1991).
12. Terman, J. R. & Kashina, A. Post-translational modification and regulation of actin. *Curr. Opin. Cell Biol.* **25**, 30–38 (2013).
13. Bhattacharya, B., Saha, S. & Sarkar, P. K. Post-transcriptional regulation of tubulin mRNA in developing rat brain. *Brain Res. Mol. Brain Res.* **10**, 347–350 (1991).
14. Urmenyi, T. P., De Castro, F. T., Carvalho, J. F., De Souza, W. & Rondonelli, E. Transcriptional and post-transcriptional control of tubulin gene expression in *Trypanosoma cruzi*. *DNA Cell Biol.* **11**, 101–109 (1992).
15. Song, Y. & Brady, S. T. Post-translational modifications of tubulin: pathways to functional diversity of microtubules. *Trends Cell Biol.* **25**, 125–136 (2015).
16. Lyubimova, A., Bershadsky, A. D. & Ben-Ze'ev, A. Autoregulation of actin synthesis responds to monomeric actin levels. *J. Cell. Biochem.* **65**, 469–478 (1997).
17. Pachter, J. S., Yen, T. J. & Cleveland, D. W. Autoregulation of tubulin expression is achieved through specific degradation of polysomal tubulin mRNAs. *Cell* **51**, 283–292 (1987).
18. Reuner, K. H., Schlegel, K., Just, I., Aktories, K. & Katz, N. Autoregulatory control of actin synthesis in cultured rat hepatocytes. *FEBS Lett.* **286**, 100–104 (1991).
19. Reuner, K. H., Wiederhold, M., Dunker, P., Just, I., Bohle, R. M. et al. Auto-regulation of actin synthesis in hepatocytes by transcriptional and post-transcriptional mechanisms. *Eur. J. Biochem.* **230**, 32–37 (1995).
20. Cleveland, D. W., Lopata, M. A., Sherline, P. & Kirschner, M. W. Unpolymerized tubulin modulates the level of tubulin mRNAs. *Cell* **25**, 537–546 (1981).
21. Yen, T. J., Gay, D. A., Pachter, J. S. & Cleveland, D. W. Autoregulated changes in stability of polyribosome-bound beta-tubulin mRNAs are specified by the first 13 translated nucleotides. *Mol. Cell. Biol.* **8**, 1224–1235 (1988).
22. Yen, T. J., Machlin, P. S. & Cleveland, D. W. Autoregulated instability of beta-tubulin mRNAs by recognition of the nascent amino terminus of beta-tubulin. *Nature* **334**, 580–585 (1988).
23. Schaefer, A., Nethe, M. & Hordijk, P. L. Ubiquitin links to cytoskeletal dynamics, cell adhesion and migration. *Biochem. J.* **442**, 13–25 (2012).
24. Schreiber, J., Vegh, M. J., Dawitz, J., Kroon, T., Loos, M. et al. Ubiquitin ligase TRIM3 controls hippocampal plasticity and learning by regulating synaptic gamma-actin levels. *J. Cell Biol.* **211**, 569–586 (2015).
25. Ren, Y., Zhao, J. & Feng, J. Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation. *J. Neurosci.* **23**, 3316–3324 (2003).
26. Herman, I. M. Actin isoforms. *Curr. Opin. Cell Biol.* **5**, 48–55 (1993).
27. Perrin, B. J. & Ervasti, J. M. The actin gene family: function follows isoform. *Cytoskeleton* **67**, 630–634 (2010).
28. Kashina, A. S. Regulation of actin isoforms in cellular and developmental processes. *Semin. Cell Dev. Biol.* **102**, 113–121 (2020).
29. Heissler, S. M. & Chinthalapudi, K. Structural and functional mechanisms of actin isoforms. *FEBS J.* **292**, 468–482 (2025).
30. Xu, M., Gonzalez-Hurtado, E. & Martinez, E. Core promoter-specific gene regulation: TATA box selectivity and Initiator-dependent bi-directionality of serum response factor-activated transcription. *Biochim. Biophys. Acta.* **1859**, 553–563 (2016).
31. Liu, Z. J., Moav, B., Faras, A. J., Guise, K. S., Kapuscinski, A. R. et al. Importance of the CArG box in regulation of beta-actin-encoding genes. *Gene* **108**, 211–217 (1991).
32. Busek, S. U., Fantappie, M., Malaquias, L. C., Wilson, R. A., Correa-Oliveira, R. et al. Cis-acting elements, CArG-, E-, CCAAT- and TATA-boxes may be involved in sexually regulated gene transcription in *Schistosoma mansoni*. *Mem. Inst. Oswaldo Cruz.* **97**, 85–90 (2002).
33. Miwa, T., Boxer, L. M. & Kedes, L. CArG boxes in the human cardiac alpha-actin gene are core binding sites for positive trans-acting regulatory factors. *Proc. Natl. Acad. Sci. USA* **84**, 6702–6706 (1987).
34. Posern, G., Sotiropoulos, A. & Treisman, R. Mutant actins demonstrate a role for unpolymerized actin in control of transcription by serum response factor. *Mol. Biol. Cell* **13**, 4167–4178 (2002).
35. Danilition, S. L., Frederickson, R. M., Taylor, C. Y. & Miyamoto, N. G. Transcription factor binding and spacing constraints in the human beta-actin proximal promoter. *Nucleic Acids Res.* **19**, 6913–6922 (1991).
36. Muscat, G. E., Perry, S., Prentice, H. & Kedes, L. The human skeletal alpha-actin gene is regulated by a muscle-specific enhancer that binds three nuclear factors. *Gene Expr.* **2**, 111–126 (1992).
37. Maliekal, T. T., Dharmapal, D. & Sengupta, S. Tubulin isotypes: emerging roles in defining cancer stem cell niche. *Front. Immunol.* **13**, 876278 (2022).
38. Duly, A. M. P., Kao, F. C. L., Teo, W. S. & Kavallaris, M. β III-tubulin gene regulation in health and disease. *Front. Cell. Dev. Biol.* **10**, 851542 (2022).
39. Leandro-Garcia, L. J., Leskela, S., Landa, I., Montero-Conde, C., Lopez-Jimenez, E. et al. Tumoral and tissue-specific expression of the major human beta-tubulin isotypes. *Cytoskeleton* **67**, 214–223 (2010).
40. Katsatos, C. D., Herman, M. M. & Mork, S. J. Class III beta-tubulin in human development and cancer. *Cell Motil. Cytoskelet.* **55**, 77–96 (2003).
41. Miller, F. D., Naus, C. C., Durand, M., Bloom, F. E. & Milner, R. J. Isotypes of alpha-tubulin are differentially regulated during neuronal maturation. *J. Cell Biol.* **105**, 3065–3073 (1987).
42. Guo, J., Walss-Bass, C. & Luduena, R. F. The beta isotypes of tubulin in neuronal differentiation. *Cytoskeleton* **67**, 431–441 (2010).
43. Haustrat, T. J., Radwitz, J., Lombino, F. L., Breiden, P. & Kneussel, M. Alpha- and beta-tubulin isotypes are differentially expressed during brain development. *Dev. Neurobiol.* **81**, 333–350 (2021).
44. Breuss, M. W., Leca, I., Gstrein, T., Hansen, A. H. & Keays, D. A. Tubulins and brain development—the origins of functional specification. *Mol. Cell. Neurosci.* **84**, 58–67 (2017).
45. Tondelir, D., Vandamme, D., Vandekerckhove, J., Ampe, C. & Lambrechts, A. Actin isoform expression patterns during mammalian development and in pathology: insights from mouse models. *Cell Motil. Cytoskeleton* **66**, 798–815 (2009).
46. Ilkovski, B., Clement, S., Sewry, C., North, K. N. & Cooper, S. T. Defining alpha-skeletal and alpha-cardiac actin expression in human heart and skeletal muscle explains the absence of cardiac involvement in ACTA1 nemaline myopathy. *Neuromuscul. Disord.* **15**, 829–835 (2005).
47. Bunnell, T. M. & Ervasti, J. M. Delayed embryonic development and impaired cell growth and survival in Actg1 null mice. *Cytoskeleton* **67**, 564–572 (2010).
48. Shawlot, W., Deng, J. M., Fohn, L. E. & Behringer, R. R. Restricted beta-galactosidase expression of a hygromycin-lacZ gene targeted to the beta-actin locus and embryonic lethality of beta-actin mutant mice. *Transgenic Res.* **7**, 95–103 (1998).
49. Ferreira, A. & Caceres, A. Expression of the class III beta-tubulin isotype in developing neurons in culture. *J. Neurosci. Res.* **32**, 516–529 (1992).
50. Gloster, A., El-Bizri, H., Bamji, S. X., Rogers, D. & Miller, F. D. Early induction of Ta1 alpha-tubulin transcription in neurons of the developing nervous system. *J. Comp. Neurol.* **405**, 45–60 (1999).
51. Tischfield, M. A., Baris, H. N., Wu, C., Rudolph, G., Van Maldergem, L. et al. Human TUBB3 mutations perturb microtubule dynamics, kinesin interactions, and axon guidance. *Cell* **140**, 74–87 (2010).
52. Keays, D. A., Tian, G., Poirier, K., Huang, G., Siebold, C. et al. Mutations in alpha-tubulin cause abnormal neuronal migration in mice and lissencephaly in humans. *Cell* **128**, 45–57 (2007).
53. Poirier, K., Keays, D. A., Francis, F., Saillour, Y., Bahi, N. et al. Large spectrum of lissencephaly and pachygyria phenotypes resulting from de novo missense mutations in tubulin alpha 1A (TUBA1A). *Hum. Mutat.* **28**, 1055–1064 (2007).
54. Ridley, A. J., Schwartz, M. A., Burridge, K., Firtel, R. A., Ginsberg, M. H. et al. Cell migration: integrating signals from front to back. *Science* **302**, 1704–1709 (2003).
55. Hall, A. Rho GTPases and the actin cytoskeleton. *Science* **279**, 509–514 (1998).
56. Mammoth, T. & Ingber, D. E. Mechanical control of tissue and organ development. *Development* **137**, 1407–1420 (2010).
57. Miralles, F., Posern, G., Zaromytidou, A. & Treisman, R. Actin dynamics control SRF activity by regulation of its coactivator MAL. *Cell* **113**, 329–342 (2003).
58. Vartiainen, M. K., Guettler, S., Larijani, B. & Treisman, R. Nuclear actin regulates dynamic subcellular localization and activity of the SRF coactivator MAL. *Science* **316**, 1749–1752 (2007).
59. Olson, E. N. & Nordheim, A. Linking actin dynamics and gene transcription to drive cellular motile functions. *Nat. Rev. Mol. Cell Biol.* **11**, 353–365 (2010).
60. Michiels, F., Wolk, A. & Renkawitz-Pohl, R. Further sequence requirements for male germ cell-specific expression under the control of the 14 bp promoter element (beta 2UE1) of the *Drosophila* beta 2 tubulin gene. *Nucleic Acids Res.* **19**, 4515–4521 (1991).
61. Santel, A., Kaufmann, J., Hyland, R. & Renkawitz-Pohl, R. The initiator element of the *Drosophila* β 2 tubulin gene core promoter contributes to gene expression *in vivo* but is not required for male germ-cell specific expression. *Nucleic Acids Res.* **28**, 1439–1446 (2000).
62. Hieber, V., Dai, X., Foreman, M. & Goldman, D. Induction of a1-tubulin gene expression during development and regeneration of the fish central nervous system. *J. Neurobiol.* **37**, 429–440 (1998).
63. Goldman, D. & Ding, J. Different regulatory elements are necessary for a1 tubulin induction during CNS development and regeneration. *NeuroReport* **11**, 3859–3863 (2000).
64. Arai, K., Matsumoto, Y., Nagashima, Y. & Yagasaki, K. Regulation of class II β -tubulin expression by tumor suppressor p53 protein in mouse melanoma cells in response to Vinca alkaloid. *Mol. Cancer. Res.* **4**, 247–255 (2006).
65. Raspaglio, G., Filippetti, F., Prislevi, S., Penci, R., De Maria, I. et al. Hypoxia induces class III beta-tubulin gene expression by HIF-1 α binding to its 3' flanking region. *Gene* **409**, 100–108 (2008).
66. Lin, Z., Gasic, I., Chandrasekaran, V., Peters, N., Shao, S. et al. TTC5 mediates autoregulation of tubulin via mRNA degradation. *Science* **367**, 100–104 (2020).

67. Hopfler, M., Absmeier, E., Peak-Chew, S., Vartholomaiou, E., Passmore, L. A. et al. Mechanism of ribosome-associated mRNA degradation during tubulin auto-regulation. *Mol. Cell* **83**, 2290–2302.e13 (2023).

68. Cho, Y., Hwang, J. W., Bedford, M. T., Song, D., Kim, S. et al. CARM1 regulates tubulin autoregulation through PI3KC2a R175 methylation. *Cell. Commun. Signal.* **23**, 120–z (2025).

69. Gulluni, F., De Santis, M. C., Margaria, J. P., Martini, M. & Hirsch, E. Class II PI3K functions in cell biology and disease. *Trends Cell Biol.* **29**, 339–359 (2019).

70. Cho, Y., Hwang, J. W., Bedford, M. T., Na, D. H., Song, D. et al. Reversible arginine methylation of PI3KC2a controls mitotic spindle dynamics. *Cell. Commun. Signal.* **23**, 409–1 (2025).

71. Batiuk, A., Hopfler, M., Almeida, A. C., Teoh En-Jie, D., Vadas, O. et al. Soluble α -tubulins reversibly sequester TTCS to regulate tubulin mRNA decay. *Nat. Commun.* **15**, 9963–0 (2024).

72. Serpinskaya, A. S., Denisenko, O. N., Gelfand, V. I. & Bershadsky, A. D. Stimulation of actin synthesis in phalloidin-treated cells. Evidence for autoregulatory control. *FEBS Lett.* **277**, 11–14 (1990).

73. Erba, H. P., Eddy, R., Shows, T., Kedes, L. & Gunning, P. Structure, chromosome location, and expression of the human gamma-actin gene: differential evolution, location, and expression of the cytoskeletal beta- and gamma-actin genes. *Mol. Cell. Biol.* **8**, 1775–1789 (1988).

74. Patrinostro, X., O'Rourke, A. R., Chamberlain, C. M., Moriarity, B. S., Perrin, B. J. et al. Relative importance of beta(cyto)- and gamma(cyto)-actin in primary mouse embryonic fibroblasts. *Mol. Biol. Cell* **28**, 771–782 (2017).

75. Rodriguez, A. & Kashina, A. Posttranscriptional and posttranslational regulation of actin. *Anat. Rec.* **301**, 1991–1998 (2018).

76. Reuner, K. H., van der Does, A., Dunker, P., Just, I., Aktories, K. et al. Microinjection of ADP-ribosylated actin inhibits actin synthesis in hepatocyte-hepatoma hybrid cells. *Biochem. J.* **319**(Pt 3), 843–849 (1996).

77. Kislauskis, E. H., Li, Z., Singer, R. H. & Taneja, K. L. Isoform-specific 3'-untranslated sequences sort alpha-cardiac and beta-cytoplasmic actin messenger RNAs to different cytoplasmic compartments. *J. Cell Biol.* **123**, 165–172 (1993).

78. Kislauskis, E. H., Zhu, X. & Singer, R. H. Sequences responsible for intracellular localization of beta-actin messenger RNA also affect cell phenotype. *J. Cell Biol.* **127**, 441–451 (1994).

79. Ross, A. F., Oleynikov, Y., Kislauskis, E. H., Taneja, K. L. & Singer, R. H. Characterization of a beta-actin mRNA zipcode-binding protein. *Mol. Cell. Biol.* **17**, 2158–2165 (1997).

80. Farina, K. L., Huttelmaier, S., Musunuru, K., Darnell, R. & Singer, R. H. Two ZBP1 KH domains facilitate beta-actin mRNA localization, granule formation, and cytoskeletal attachment. *J. Cell Biol.* **160**, 77–87 (2003).

81. Oleynikov, Y. & Singer, R. H. Real-time visualization of ZBP1 association with beta-actin mRNA during transcription and localization. *Curr. Biol.* **13**, 199–207 (2003).

82. Mouilleron, S., Guettler, S., Langer, C. A., Treisman, R. & McDonald, N. Q. Molecular basis for G-actin binding to RPEL motifs from the serum response factor coactivator MAL. *EMBO J.* **27**, 3198–3208 (2008).

83. Mouilleron, S., Langer, C. A., Guettler, S., McDonald, N. Q. & Treisman, R. Structure of a pentavalent G-actin*MRFT-A complex reveals how G-actin controls nucleocytoplasmic shuttling of a transcriptional coactivator. *Sci. Signal.* **4**, ra40 (2011).

84. Mohun, T., Garrett, N. & Treisman, R. *Xenopus* cytoskeletal actin and human c-fos gene promoters share a conserved protein-binding site. *EMBO J.* **6**, 667–673 (1987).

85. Sotiropoulos, A., Gineitis, D., Copeland, J. & Treisman, R. Signal-regulated activation of serum response factor is mediated by changes in actin dynamics. *Cell* **98**, 159–169 (1999).

86. Salvany, L., Muller, J., Guccione, E. & Rorth, P. The core and conserved role of MAL is homeostatic regulation of actin levels. *Genes Dev.* **28**, 1048–1053 (2014).

87. Percipalle, P. & Visa, N. Molecular functions of nuclear actin in transcription. *J. Cell Biol.* **172**, 967–971 (2006).

88. Visa, N. & Percipalle, P. Nuclear functions of actin. *Cold Spring Harb. Perspect. Biol.* **2**, a000620 (2010).

89. Kelpsch, D. J. & Tootle, T. L. Nuclear actin: from discovery to function. *Anat. Rec.* **301**, 1999–2013 (2018).

90. Caridi, C. P., D'Agostino, C., Ryu, T., Zapotoczny, G., Delabaere, L. et al. Nuclear F-actin and myosins drive relocation of heterochromatic breaks. *Nature* **559**, 54–60 (2018).

91. Sen, B., Xie, Z., Thomas, M. D., Pattenden, S. G., Howard, S. et al. Nuclear actin structure regulates chromatin accessibility. *Nat. Commun.* **15**, 4095–y (2024).

92. Huang, Y., Zhang, S. & Park, J. Nuclear actin dynamics in gene expression, DNA repair, and cancer. *Results Probl. Cell Differ.* **70**, 625–663 (2022).

93. Dopie, J., Skarp, K., Rajakyla, E. K., Tanhuanpaa, K. & Vartiainen, M. K. Active maintenance of nuclear actin by importin 9 supports transcription. *Proc. Natl. Acad. Sci. USA* **109**, 544 (2012).

94. Dopie, J., Rajakyla, E. K., Joensuu, M. S., Huet, G., Ferrantelli, E. et al. Genome-wide RNAi screen for nuclear actin reveals a network of cofilin regulators. *J. Cell. Sci.* **128**, 2388–2400 (2015).

95. Stuven, T., Hartmann, E. & Gorlich, D. Exportin 6: a novel nuclear export receptor that is specific for profilin.actin complexes. *EMBO J.* **22**, 5928–5940 (2003).

96. Krishnan, K. & Moens, P. D. J. Structure and functions of profilins. *Biophys. Rev.* **1**, 71–81 (2009).

97. Grossé, R. & Vartiainen, M. K. To be or not to be assembled: progressing into nuclear actin filaments. *Nat. Rev. Mol. Cell Biol.* **14**, 693–697 (2013).

98. Weissman, A. M. Themes and variations on ubiquitylation. *Nat. Rev. Mol. Cell Biol.* **2**, 169–178 (2001).

99. Weissman, A. M., Shabek, N. & Ciechanover, A. The predator becomes the prey: regulating the ubiquitin system by ubiquitylation and degradation. *Nat. Rev. Mol. Cell Biol.* **12**, 605–620 (2011).

100. Peters, J. M. Proteasomes: protein degradation machines of the cell. *Trends Biochem. Sci.* **19**, 377–382 (1994).

101. Turgu, B., El-Naggar, A., Kogler, M., Tortola, L., Zhang, H. et al. The HACE1 E3 ligase mediates RAC1-dependent control of mTOR signaling complexes. *EMBO Rep.* **24**, e56815 (2023).

102. Oberoi-Khanu, T. K. & Rajalingam, K. IAPs as E3 ligases of Rac1: shaping the move. *Small GTPases* **3**, 131–136 (2012).

103. Zhao, J., Mialki, R. K., Wei, J., Coon, T. A., Zou, C. et al. SCF(FBXL19) regulates cell migration by mediating Rac1 ubiquitination and degradation. *FASEB J.* **27**, 2611–2619 (2013).

104. Chen, Y., Yang, Z., Meng, M., Zhao, Y., Dong, N. et al. Cullin mediates degradation of RhoA through evolutionarily conserved BTB adaptors to control actin cytoskeleton structure and cell movement. *Mol. Cell* **35**, 841–855 (2009).

105. Wei, J., Mialki, R. K., Dong, S., Khoo, A., Mallampalli, R. K. et al. A new mechanism of RhoA ubiquitination and degradation: roles of SCF(FBXL19) E3 ligase and Erk2. *Biochim. Biophys. Acta.* **1833**, 2757–2764 (2013).

106. Wang, H., Ogunjimi, A. A., Zhang, Y., Ozdamar, B., Bose, R. et al. Degradation of RhoA by Smurfl ubiquitin ligase. *Methods Enzymol.* **406**, 437–447 (2006).

107. Murali, A., Shin, J., Jurugi, H., Krishnan, A., Akutsu, M. et al. Ubiquitin-dependent regulation of Cdc42 by XIAP. *Cell. Death Dis.* **8**, e2900 (2017).

108. Dou, Q., Chen, H., Wang, K., Yuan, K., Lei, Y. et al. Ivermectin induces cytostatic autophagy by blocking the PAK1/Akt axis in breast cancer. *Cancer Res.* **76**, 4457–4469 (2016).

109. Bobo-Jimenez, V., Delgado-Esteban, M., Angibaud, J., Sanchez-Moran, I., de la Fuente, A. et al. APC/C(Cdh1)-Rock2 pathway controls dendritic integrity and memory. *Proc. Natl. Acad. Sci. USA* **114**, 4513–4518 (2017).

110. Gainullin, M. R., Zhukov, I. Y., Zhou, X., Mo, Y., Astakhova, L. et al. Degradation of cofilin is regulated by Cbl, AIP4 and Syk resulting in increased migration of LMP2A positive nasopharyngeal carcinoma cells. *Sci. Rep.* **7**, 9012–3 (2017).

111. Murti, K. G., Smith, H. T. & Fried, V. A. Ubiquitin is a component of the microtubule network. *Proc. Natl. Acad. Sci. USA* **85**, 3019–3023 (1988).

112. Yin, C., Lui, E. S. W., Jiang, T. & Qi, R. Z. Proteolysis of gamma-tubulin small complex proteins is mediated by the ubiquitin–proteasome system. *FEBS Lett.* **595**, 1987–1996 (2021).

113. Petrucelli, L., Dickson, D., Kehoe, K., Taylor, J., Snyder, H. et al. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. *Hum. Mol. Genet.* **13**, 703–714 (2004).

114. Aoki, S., Onodera, W., Takashima, A., Kawasaki, K., Imaedegawa, K. et al. E3 ligase Praja1 mediates ubiquitination and degradation of microtubule-associated protein Tau. *iFEBS J.* <https://doi.org/10.1111/febs.70303> (2025).

115. Subramanian, M., Hyeon, S. J., Das, T., Suh, Y. S., Kim, Y. K. et al. UBE4B, a microRNA-9 target gene, promotes autophagy-mediated Tau degradation. *Nat. Commun.* **12**, 3291–9 (2021).

116. Starita, L. M., Machida, Y., Sankaran, S., Elias, J. E., Griffin, K. et al. BRCA1-dependent ubiquitination of gamma-tubulin regulates centrosome number. *Mol. Cell. Biol.* **24**, 8457–8466 (2004).

117. Sankaran, S., Crone, D. E., Palazzo, R. E. & Parvin, J. D. BRCA1 regulates gamma-tubulin binding to centrosomes. *Cancer. Biol. Ther.* **6**, 1853–1857 (2007).

118. Srivastava, D. & Chakrabarti, O. Mahogunin-mediated alpha-tubulin ubiquitination via noncanonical K6 linkage regulates microtubule stability and mitotic spindle orientation. *Cell. Death Dis.* **5**, e1064 (2014).

119. Mukherjee, R., Majumder, P. & Chakrabarti, O. MGRN1-mediated ubiquitination of alpha-tubulin regulates microtubule dynamics and intracellular transport. *Traffic* **18**, 791–807 (2017).

120. Binarova, P. & Tuszyński, J. Tubulin: structure, functions and roles in disease. *Cells* **8**, 1294 (2019).

121. Parker, F., Baboolal, T. G. & Peckham, M. Actin mutations and their role in disease. *Int. J. Mol. Sci.* **21**, 3371 (2020).

122. Clarkson, E., Costa, C. F. & Machesky, L. M. Congenital myopathies: diseases of the actin cytoskeleton. *J. Pathol.* **204**, 407–417 (2004).

123. Yadunandan Nair, N., Samuel, V., Ramesh, L., Marib, A., David, D. T. et al. Actin cytoskeleton in angiogenesis. *Biol. Open* **11**, bio058899 (2022).

124. Parmacek, M. S. Myocardin-related transcription factors: critical coactivators regulating cardiovascular development and adaptation. *Circ. Res.* **100**, 633–644 (2007).

125. Tsou, P., Haak, A. J., Khanna, D. & Neubig, R. R. Cellular mechanisms of tissue fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription. *Am. J. Physiol. Cell. Physiol.* **307**, 2 (2014).

126. Dee, R. A., Mangum, K. D., Bai, X., Mack, C. P. & Taylor, J. M. Druggable targets in the Rho pathway and their promise for therapeutic control of blood pressure. *Pharmacol. Ther.* **193**, 121–134 (2019).

127. Boiarska, Z. & Passarella, D. Microtubule-targeting agents and neurodegeneration. *Drug Discov. Today* **26**, 604–615 (2021).

128. Parker, A. L., Teo, W. S., McCarroll, J. A. & Kavallaris, M. An emerging role for tubulin isotypes in modulating cancer biology and chemotherapy resistance. *Int. J. Mol. Sci.* **18**, 1434 (2017).

129. Prassanawar, S. S. & Panda, D. Tubulin heterogeneity regulates functions and dynamics of microtubules and plays a role in the development of drug resistance in cancer. *Biochem. J.* **476**, 1359–1376 (2019).

130. Jordan, M. A. & Wilson, L. Microtubules as a target for anticancer drugs. *Nat. Rev. Cancer.* **4**, 253–265 (2004).

131. Ojima, I. & Ferlini, C. New insights into drug resistance in cancer. *Chem. Biol.* **10**, 583–584 (2003).

132. Wallgren-Pettersson, C., Sewry, C. A., Nowak, K. J. & Laing, N. G. Nemaline myopathies. *Semin. Pediatr. Neurol.* **18**, 230–238 (2011).

133. Nowak, K. J., Ravenscroft, G. & Laing, N. G. Skeletal muscle alpha-actin diseases (actinopathies): pathology and mechanisms. *Acta Neuropathol.* **125**, 19–32 (2013).

134. Guo, D., Pannu, H., Tran-Fadulu, V., Papke, C. L., Yu, R. K. et al. Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissections. *Nat. Genet.* **39**, 1488–1493 (2007).

135. Olson, T. M., Michels, V. V., Thibodeau, S. N., Tai, Y. S. & Keating, M. T. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. *Science* **280**, 750–752 (1998).

136. Mogensen, J., Klausen, I. C., Pedersen, A. K., Egeblad, H., Bross, P. et al. Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. *J. Clin. Invest.* **103**, 39 (1999).

137. Riviere, J., van Bon, B. W. M., Hoischen, A., Kholmanskikh, S. S., O'Roak, B. J. et al. De novo mutations in the actin genes ACTB and ACTG1 cause Baraitser-Winter syndrome. *Nat. Genet.* **44**, 440–2 (2012).

138. Yates, T. M., Turner, C. L., Firth, H. V., Berg, J. & Pilz, D. T. Baraitser-Winter cerebrofrontofacial syndrome. *Clin. Genet.* **92**, 3–9 (2017).

139. Belyantseva, I. A., Perrin, B. J., Sonnemann, K. J., Zhu, M., Stepanyan, R. et al. Gamma-actin is required for cytoskeletal maintenance but not development. *Proc. Natl. Acad. Sci. USA* **106**, 9703–9708 (2009).

140. Di Donato, N., Kuechler, A., Vergano, S., Heinritz, W., Bodurtha, J. et al. Update on the ACTG1-associated Baraitser-Winter cerebrofrontofacial syndrome. *Am. J. Med. Genet. A* **170**, 2644–2651 (2016).

141. Wangler, M. F., Gonzaga-Jauregui, C., Gambin, T., Penney, S., Moss, T. et al. Heterozygous de novo and inherited mutations in the smooth muscle actin (ACTG2) gene underlie megacystis-microcolon-intestinal hypoperistalsis syndrome. *PLoS Genet.* **10**, e1004258 (2014).

142. Ravenscroft, G., Pannell, S., O'Grady, G., Ong, R., Ee, H. C. et al. Variants in ACTG2 underlie a substantial number of Australasian patients with primary chronic intestinal pseudo-obstruction. *Neurogastroenterol. Motil.* **30**, e13371 (2018).

143. Izdebska, M., Zielinska, W., Grzanka, D. & Gagat, M. The role of actin dynamics and actin-binding proteins expression in epithelial-to-mesenchymal transition and its association with cancer progression and evaluation of possible therapeutic targets. *Biomed. Res. Int.* **2018**, 4578373 (2018).

144. McCarroll, J. A., Sharbeen, G., Liu, J., Youkhana, J., Goldstein, D. et al. β III-tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancer. *Oncotarget* **6**, 2235–2249 (2015).

145. Biber, G., Ben-Shmuel, A., Sabag, B. & Barda-Saad, M. Actin regulators in cancer progression and metastases: from structure and function to cytoskeletal dynamics. *Int. Rev. Cell. Mol. Biol.* **356**, 131–196 (2020).

146. Wang, W., Eddy, R. & Condeelis, J. The cofilin pathway in breast cancer invasion and metastasis. *Nat. Rev. Cancer.* **7**, 429–440 (2007).

147. Coumans, J. V. F., Davey, R. J. & Moens, P. D. J. Cofilin and profilin: partners in cancer aggressiveness. *Biophys. Rev.* **10**, 1323–1335 (2018).

148. Zheng, S., Qin, F., Yin, J., Li, D., Huang, Y. et al. Role and mechanism of actin-related protein 2/3 complex signaling in cancer invasion and metastasis: a review. *Medicine* **102**, e33158 (2023).

149. Dugina, V., Khromova, N., Rybko, V., Blizniukov, O., Shagieva, G. et al. Tumor promotion by gamma and suppression by beta non-muscle actin isoforms. *Oncotarget* **6**, 14556–14571 (2015).

150. Dugina, V. B., Shagieva, G. S. & Kopnin, P. B. Cytoplasmic beta and gamma actin isoforms reorganization and regulation in tumor cells in culture and tissue. *Front. Pharmacol.* **13**, 895703 (2022).

151. Shestakova, E. A., Wyckoff, J., Singer, R. H. & Condeelis, J. Correlation of beta-actin messenger RNA localization with metastatic potential in rat adenocarcinoma cell lines. *Cancer Res.* **59**, 1202–5 (1999).

152. Lai, W. & Wong, W. Roles of the actin cytoskeleton in aging and age-associated diseases. *Ageing Res. Rev.* **58**, 101021 (2020).

153. Yao, L., Romero, M. J., Toque, H. A., Yang, G., Caldwell, R. B. et al. The role of RhoA/Rho kinase pathway in endothelial dysfunction. *J. Cardiovasc. Dis. Res.* **1**, 165–170 (2010).

154. Hauke, M., Eckenstaller, R., Ripperger, A., Ender, A., Braun, H. et al. Active RhoA exerts an inhibitory effect on the homeostasis and angiogenic capacity of human endothelial cells. *J. Am. Heart Assoc.* **11**, e025119 (2022).

155. Masumoto, A., Hirooka, Y., Shimokawa, H., Hironaga, K., Setoguchi, S. et al. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. *Hypertension* **38**, 1307–1310 (2001).

156. Tanna, A. P. & Johnson, M. Rho kinase inhibitors as a novel treatment for glaucoma and ocular hypertension. *Ophthalmology* **125**, 1741–1756 (2018).

157. Yamamoto, M., Marui, N., Sakai, T., Morii, N., Kozaki, S. et al. ADP-ribosylation of the rhoA gene product by botulinum C3 exoenzyme causes Swiss 3T3 cells to accumulate in the G1 phase of the cell cycle. *Oncogene* **8**, 1449–1455 (1993).

158. Shang, X., Marchioni, F., Sipes, N., Evelyn, C. R., Jerabek-Willemse, M. et al. Rational design of small molecule inhibitors targeting RhoA subfamily Rho GTPases. *Chem. Biol.* **19**, 699–710 (2012).

159. Cooper, J. A. Effects of cytochalasin and phalloidin on actin. *J. Cell Biol.* **105**, 1473–1478 (1987).

160. Coue, M., Brenner, S. L., Spector, I. & Korn, E. D. Inhibition of actin polymerization by latrunculin A. *FEBS Lett.* **213**, 316–318 (1987).

161. Bubb, M. R., Senderowicz, A. M., Sausville, E. A., Duncan, K. L. & Korn, E. D. Jasplakinolide, a cytotoxic natural product, induces actin polymerization and competitively inhibits the binding of phalloidin to F-actin. *J. Biol. Chem.* **269**, 14869–14871 (1994).

162. Bahi-Buisson, N., Poirier, K., Fourniol, F., Saillour, Y., Valence, S. et al. The wide spectrum of tubulinopathies: what are the key features for the diagnosis? *Brain* **137**, 1676–1700 (2014).

163. Poirier, K., Saillour, Y., Fourniol, F., Francis, F., Souville, I. et al. Expanding the spectrum of TUBA1A-related cortical dysgenesis to Polymicrogyria. *Eur. J. Hum. Genet.* **21**, 381–385 (2013).

164. Jaglin, X. H., Poirier, K., Saillour, Y., Buhler, E., Tian, G. et al. Mutations in the beta-tubulin gene TUBB2B result in asymmetrical polymicrogyria. *Nat. Genet.* **41**, 746–752 (2009).

165. Hersheson, J., Mencacci, N. E., Davis, M., MacDonald, N., Trabzuni, D. et al. Mutations in the autoregulatory domain of beta-tubulin 4a cause hereditary dystonia. *Ann. Neurol.* **73**, 546–553 (2013).

166. Ivanova, E. L., Gilet, J. G., Sulimenko, V., Duchon, A., Rudolf, G. et al. TUBG1 missense variants underlying cortical malformations disrupt neuronal locomotion and microtubule dynamics but not neurogenesis. *Nat. Commun.* **10**, 2129–8 (2019).

167. Shen, R., Zhang, Z., Zhuang, Y., Yang, X. & Duan, L. A novel TUBG1 mutation with neurodevelopmental disorder caused by malformations of cortical development. *Biomed. Res. Int.* **2021**, 6644274 (2021).

168. Fourel, G. & Boscheron, C. Tubulin mutations in neurodevelopmental disorders as a tool to decipher microtubule function. *FEBS Lett.* **594**, 3409–3438 (2020).

169. Nogales, E., Whittaker, M., Milligan, R. A. & Downing, K. H. High-resolution model of the microtubule. *Cell* **96**, 79–88 (1999).

170. Li, H., DeRosier, D. J., Nicholson, W. V., Nogales, E. & Downing, K. H. Microtubule structure at 8 Å resolution. *Structure* **10**, 1317–1328 (2002).

171. Musante, L., Faletta, F., Meier, K., Tomoum, H., Najjarzadeh Torbati, P. et al. TTCS syndrome: clinical and molecular spectrum of a severe and recognizable condition. *Am. J. Med. Genet. A* **188**, 2652–2665 (2022).

172. Tiosano, D., Baris, H. N., Chen, A., Hitzert, M. M., Schueler, M. et al. Mutations in PIK3C2A cause syndromic short stature, skeletal abnormalities, and cataracts associated with ciliary dysfunction. *PLoS Genet.* **15**, e1008088 (2019).

173. Pham, C. L. & Morrisette, N. S. The tubulin mutation database: a resource for the cytoskeleton community. *Cytoskeleton* **76**, 186–191 (2019).

174. Roll-Mecak, A. Intrinsically disordered tubulin tails: complex tuners of microtubule functions? *Semin. Cell Dev. Biol.* **37**, 11–19 (2015).

175. Shida, T., Cueva, J. G., Xu, Z., Goodman, M. B. & Nachury, M. V. The major alpha-tubulin K40 acetyltransferase α TAT1 promotes rapid ciliogenesis and efficient mechanosensation. *Proc. Natl. Acad. Sci. USA* **107**, 21517–21522 (2010).

176. Lu, Y. Reinterpreting the effects of alpha-tubulin K40 acetylation on microtubule stability and cellular functions. *J. Cell. Sci.* **138**, jcs263431 (2025).

177. Park, I. Y., Powell, R. T., Tripathi, D. N., Dere, R., Ho, T. H. et al. Dual chromatin and cytoskeletal remodeling by SETD2. *Cell* **166**, 950–962 (2016).

178. Kearns, S., Mason, F. M., Rathmell, W. K., Park, I. Y., Walker, C. et al. Molecular determinants for alpha-tubulin methylation by SETD2. *J. Biol. Chem.* **297**, 100898 (2021).

179. Sun, S., Xu, Z., He, L., Shen, Y., Yan, Y. et al. Metabolic regulation of cytoskeleton functions by HDAC6-catalyzed alpha-tubulin lactylation. *Nat. Commun.* **15**, 8377–0 (2024).

180. Zhao, L., Qi, H., Lv, H., Liu, W., Zhang, R. et al. Lactylation in health and disease: physiological or pathological? *Theranostics* **15**, 1787–1821 (2025).

181. Erck, C., Peris, L., Andrieux, A., Meissirel, C., Gruber, A. D. et al. A vital role of tubulin-tyrosine-ligase for neuronal organization. *Proc. Natl Acad. Sci. USA* **102**, 7853–7858 (2005).

182. Fees, C. P. & Moore, J. K. Regulation of microtubule dynamic instability by the carboxy-terminal tail of beta-tubulin. *Life. Sci. Alliance* **1**, e201800054 (2018).

183. Lopes, D. & Maiato, H. The tubulin code in mitosis and cancer. *Cells* **9**, 2356 (2020).

184. Wattanathamsan, O. & Pongrakhananon, V. Post-translational modifications of tubulin: their role in cancers and the regulation of signaling molecules. *Cancer Gene Ther.* **30**, 521–528 (2023).

185. Narvi, E., Jaakkola, K., Winsel, S., Oetken-Lindholm, C., Halonen, P. et al. Altered TUBB3 expression contributes to the epothilone response of mitotic cells. *Br. J. Cancer* **108**, 82–90 (2013).

186. Lebok, P., Ozturk, M., Heilenkötter, U., Jaenicke, F., Muller, V. et al. High levels of class III beta-tubulin expression are associated with aggressive tumor features in breast cancer. *Oncol. Lett.* **11**, 1987–1994 (2016).

187. Kanakkanthara, A. & Miller, J. H. betall-tubulin overexpression in cancer: causes, consequences, and potential therapies. *Biochim. Biophys. Acta Rev. Cancer* **1876**, 188607 (2021).

188. Ruksha, K., Mezheyevski, A., Nerovnya, A., Bich, T., Tur, G. et al. Over-expression of β II-tubulin and especially its localization in cell nuclei correlates with poorer outcomes in colorectal cancer. *Cells* **8**, 25 (2019).

189. Katsetos, C. D., Reddy, G., Draberova, E., Smejkalova, B., Del Valle, L. et al. Altered cellular distribution and subcellular sorting of gamma-tubulin in diffuse astrocytic gliomas and human glioblastoma cell lines. *J. Neuropathol. Exp. Neurol.* **65**, 465–477 (2006).

190. Zadra, I., Jimenez-Delgado, S., Anglada-Girotto, M., Segura-Morales, C., Compton, Z. J. et al. Chromosome segregation fidelity requires microtubule poly-glutamyltation by the cancer downregulated enzyme TTLL11. *Nat. Commun.* **13**, 7147–y (2022).

191. Wattanathamsan, O., Thararattanobon, R., Rodsiri, R., Chanvorachote, P., Vinayanuwattikun, C. et al. Tubulin acetylation enhances lung cancer resistance to paclitaxel-induced cell death through Mcl-1 stabilization. *Cell. Death Discov.* **7**, 67–9 (2021).

192. DeWard, A. D. & Alberts, A. S. Ubiquitin-mediated degradation of the formin mDia2 upon completion of cell division. *J. Biol. Chem.* **284**, 20061–20069 (2009).

193. Lohraseb, I., McCarthy, P., Secker, G., Marchant, C., Wu, J. et al. Global ubiquitome profiling identifies NEDD4 as a regulator of Profilin 1 and actin remodelling in neural crest cells. *Nat. Commun.* **13**, 2018–3 (2022).

194. Courtheoux, T., Enchev, R. I., Lampert, F., Gerez, J., Beck, J. et al. Cortical dynamics during cell motility are regulated by CRL3(KLHL21) E3 ubiquitin ligase. *Nat. Commun.* **7**, 12810 (2016).

195. Peth, A., Boettcher, J. P. & Dubiel, W. Ubiquitin-dependent proteolysis of the microtubule end-binding protein 1, EB1, is controlled by the COP9 signalosome: possible consequences for microtubule filament stability. *J. Mol. Biol.* **368**, 550–563 (2007).

196. Ban, R., Matsuzaki, H., Akashi, T., Sakashita, G., Taniguchi, H. et al. Mitotic regulation of the stability of microtubule plus-end tracking protein EB3 by ubiquitin ligase SIAH-1 and Aurora mitotic kinases. *J. Biol. Chem.* **284**, 28367–28381 (2009).

197. Lian, N., Liu, X., Wang, X., Zhou, Y., Li, H. et al. COP1 mediates dark-specific degradation of microtubule-associated protein WDL3 in regulating *Arabidopsis* hypocotyl elongation. *Proc. Natl Acad. Sci. USA* **114**, 12321–12326 (2017).

ACKNOWLEDGEMENTS

This study was supported by grants from the National Research Foundation of Korea (NRF) and the Korean government (MSIT) (grant numbers RS-2024-00412728 (Y.C.), RS-2025-00563180 (Y.K.K.), RS-2024-00509503 (Y.K.K.), and RS-2022-NR070845 (Y.K.K.)). Graphics were created with <https://BioRender.com>.

CONFLICT OF INTEREST

The authors declare no competing interests.

ADDITIONAL INFORMATION

Correspondence and requests for materials should be addressed to Yong Kee Kim.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2025